APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

HIV Diagnosis & Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global HIV Diagnosis & Treatment Market Outlook and Growth Opportunities 2026

Report ID 173998780420 December 2025192 pages

Choose your research edition.

Industry ResearchHIV Diagnosis & Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Diagnosis & Treatment Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal HIV Diagnosis & Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Diagnosis & Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Diagnosis & Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global HIV Diagnosis & Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for HIV Diagnosis & Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV Diagnosis & Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV Diagnosis & Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the HIV Diagnosis & Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the HIV Diagnosis & Treatment market include Abbott Laboratories, Johnson & Johnson, GlaxoSmithKline, Gilead, F. Hoffmann-La Roche, Cipla, Bristol-Myers Squibb and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global HIV Diagnosis & Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV Diagnosis & Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV Diagnosis & Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global HIV Diagnosis & Treatment market.

HIV Diagnosis & Treatment Segment by Company

Abbott Laboratories

Johnson & Johnson

GlaxoSmithKline

Gilead

F. Hoffmann-La Roche

Cipla

Bristol-Myers Squibb

Boehringer Ingelheim

HIV Diagnosis & Treatment Segment by Type

Saliva Tests

ELISA Test

Western Blot

Viral Load Test

Others

HIV Diagnosis & Treatment Segment by Application

Hospitals

Clinics

HIV Diagnosis & Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global HIV Diagnosis & Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the HIV Diagnosis & Treatment key companies, revenue, market share, and recent developments.

3. To split the HIV Diagnosis & Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions HIV Diagnosis & Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify HIV Diagnosis & Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze HIV Diagnosis & Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Diagnosis & Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Diagnosis & Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Diagnosis & Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HIV Diagnosis & Treatment industry.

Chapter 3: Detailed analysis of HIV Diagnosis & Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of HIV Diagnosis & Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of HIV Diagnosis & Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. HIV Diagnosis & Treatment Industry Trends Table 2. HIV Diagnosis & Treatment Industry Drivers Table 3. HIV Diagnosis & Treatment Industry Opportunities and Challenges Table 4. HIV Diagnosis & Treatment Industry Restraints Table 5. Global HIV Diagnosis & Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global HIV Diagnosis & Treatment Revenue Share by Company (2021-2026) Table 7. Global HIV Diagnosis & Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global HIV Diagnosis & Treatment Key Company Manufacturing Base & Headquarters Table 9. Global HIV Diagnosis & Treatment Company, Product Type & Application Table 10. Global HIV Diagnosis & Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global HIV Diagnosis & Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Saliva Tests Table 15. Significant Companies of ELISA Test Table 16. Significant Companies of Western Blot Table 17. Significant Companies of Viral Load Test Table 18. Significant Companies of Others Table 19. Global HIV Diagnosis & Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global HIV Diagnosis & Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global HIV Diagnosis & Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global HIV Diagnosis & Treatment Sales Value Share by Type (2021-2026) Table 23. Global HIV Diagnosis & Treatment Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Clinics Table 26. Global HIV Diagnosis & Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global HIV Diagnosis & Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global HIV Diagnosis & Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global HIV Diagnosis & Treatment Sales Value Share by Application (2021-2026) Table 30. Global HIV Diagnosis & Treatment Sales Value Share by Application (2027-2032) Table 31. Global HIV Diagnosis & Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global HIV Diagnosis & Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global HIV Diagnosis & Treatment Sales Value Share by Region (2021-2026) Table 34. Global HIV Diagnosis & Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global HIV Diagnosis & Treatment Sales Value Share by Region (2027-2032) Table 36. Global HIV Diagnosis & Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global HIV Diagnosis & Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global HIV Diagnosis & Treatment Sales Value Market Share by Country (2021-2026) Table 39. Global HIV Diagnosis & Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global HIV Diagnosis & Treatment Sales Value Market Share by Country (2027-2032) Table 41. Abbott Laboratories Company Information Table 42. Abbott Laboratories Business Overview Table 43. Abbott Laboratories HIV Diagnosis & Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Abbott Laboratories HIV Diagnosis & Treatment Product Portfolio Table 45. Abbott Laboratories Recent Development Table 46. Johnson & Johnson Company Information Table 47. Johnson & Johnson Business Overview Table 48. Johnson & Johnson HIV Diagnosis & Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Johnson & Johnson HIV Diagnosis & Treatment Product Portfolio Table 50. Johnson & Johnson Recent Development Table 51. GlaxoSmithKline Company Information Table 52. GlaxoSmithKline Business Overview Table 53. GlaxoSmithKline HIV Diagnosis & Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. GlaxoSmithKline HIV Diagnosis & Treatment Product Portfolio Table 55. GlaxoSmithKline Recent Development Table 56. Gilead Company Information Table 57. Gilead Business Overview Table 58. Gilead HIV Diagnosis & Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Gilead HIV Diagnosis & Treatment Product Portfolio Table 60. Gilead Recent Development Table 61. F. Hoffmann-La Roche Company Information Table 62. F. Hoffmann-La Roche Business Overview Table 63. F. Hoffmann-La Roche HIV Diagnosis & Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. F. Hoffmann-La Roche HIV Diagnosis & Treatment Product Portfolio Table 65. F. Hoffmann-La Roche Recent Development Table 66. Cipla Company Information Table 67. Cipla Business Overview Table 68. Cipla HIV Diagnosis & Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Cipla HIV Diagnosis & Treatment Product Portfolio Table 70. Cipla Recent Development Table 71. Bristol-Myers Squibb Company Information Table 72. Bristol-Myers Squibb Business Overview Table 73. Bristol-Myers Squibb HIV Diagnosis & Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bristol-Myers Squibb HIV Diagnosis & Treatment Product Portfolio Table 75. Bristol-Myers Squibb Recent Development Table 76. Boehringer Ingelheim Company Information Table 77. Boehringer Ingelheim Business Overview Table 78. Boehringer Ingelheim HIV Diagnosis & Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Boehringer Ingelheim HIV Diagnosis & Treatment Product Portfolio Table 80. Boehringer Ingelheim Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. HIV Diagnosis & Treatment Product Image Figure 2. Global HIV Diagnosis & Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Diagnosis & Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV Diagnosis & Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Saliva Tests Image Figure 8. ELISA Test Image Figure 9. Western Blot Image Figure 10. Viral Load Test Image Figure 11. Others Image Figure 12. Global HIV Diagnosis & Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global HIV Diagnosis & Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global HIV Diagnosis & Treatment Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Clinics Image Figure 17. Global HIV Diagnosis & Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global HIV Diagnosis & Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global HIV Diagnosis & Treatment Sales Value Share by Application (2021-2032) Figure 20. Global HIV Diagnosis & Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global HIV Diagnosis & Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America HIV Diagnosis & Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. North America HIV Diagnosis & Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe HIV Diagnosis & Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Europe HIV Diagnosis & Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific HIV Diagnosis & Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific HIV Diagnosis & Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America HIV Diagnosis & Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. South America HIV Diagnosis & Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa HIV Diagnosis & Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa HIV Diagnosis & Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Saliva Tests
  • ELISA Test
  • Western Blot
  • Viral Load Test
  • Others
Applications
  • Hospitals
  • Clinics
Companies covered
  • Abbott Laboratories
  • Johnson & Johnson
  • GlaxoSmithKline
  • Gilead
  • F. Hoffmann-La Roche
  • Cipla
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global HIV Diagnosis & Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global HIV Diagnosis & Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 HIV Diagnosis & Treatment Market Dynamics
  1. 2.1 HIV Diagnosis & Treatment Industry Trends
  2. 2.2 HIV Diagnosis & Treatment Industry Drivers
  3. 2.3 HIV Diagnosis & Treatment Industry Opportunities and Challenges
  4. 2.4 HIV Diagnosis & Treatment Industry Restraints
3 HIV Diagnosis & Treatment Market by Company
  1. 3.1 Global HIV Diagnosis & Treatment Company Revenue Ranking in 2025
  2. 3.2 Global HIV Diagnosis & Treatment Revenue by Company (2021-2026)
  3. 3.3 Global HIV Diagnosis & Treatment Company Ranking (2024-2026)
  4. 3.4 Global HIV Diagnosis & Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global HIV Diagnosis & Treatment Company Product Type and Application
  6. 3.6 Global HIV Diagnosis & Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global HIV Diagnosis & Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 HIV Diagnosis & Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 HIV Diagnosis & Treatment Market by Type
  1. 4.1 HIV Diagnosis & Treatment Type Introduction
  2. 4.1.1 Saliva Tests
  3. 4.1.2 ELISA Test
  4. 4.1.3 Western Blot
  5. 4.1.4 Viral Load Test
  6. 4.1.5 Others
  7. 4.2 Global HIV Diagnosis & Treatment Sales Value by Type
  8. 4.2.1 Global HIV Diagnosis & Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global HIV Diagnosis & Treatment Sales Value by Type (2021-2032)
  10. 4.2.3 Global HIV Diagnosis & Treatment Sales Value Share by Type (2021-2032)
5 HIV Diagnosis & Treatment Market by Application
  1. 5.1 HIV Diagnosis & Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.2 Global HIV Diagnosis & Treatment Sales Value by Application
  5. 5.2.1 Global HIV Diagnosis & Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global HIV Diagnosis & Treatment Sales Value by Application (2021-2032)
  7. 5.2.3 Global HIV Diagnosis & Treatment Sales Value Share by Application (2021-2032)
6 HIV Diagnosis & Treatment Regional Value Analysis
  1. 6.1 Global HIV Diagnosis & Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV Diagnosis & Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global HIV Diagnosis & Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global HIV Diagnosis & Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America HIV Diagnosis & Treatment Sales Value (2021-2032)
  7. 6.3.2 North America HIV Diagnosis & Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe HIV Diagnosis & Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe HIV Diagnosis & Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific HIV Diagnosis & Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific HIV Diagnosis & Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America HIV Diagnosis & Treatment Sales Value (2021-2032)
  16. 6.6.2 South America HIV Diagnosis & Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa HIV Diagnosis & Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa HIV Diagnosis & Treatment Sales Value Share by Country, 2025 VS 2032
7 HIV Diagnosis & Treatment Country-level Value Analysis
  1. 7.1 Global HIV Diagnosis & Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global HIV Diagnosis & Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global HIV Diagnosis & Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global HIV Diagnosis & Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt HIV Diagnosis & Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt HIV Diagnosis & Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt HIV Diagnosis & Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott Laboratories
  2. 8.1.1 Abbott Laboratories Company Information
  3. 8.1.2 Abbott Laboratories Business Overview
  4. 8.1.3 Abbott Laboratories HIV Diagnosis & Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Laboratories HIV Diagnosis & Treatment Product Portfolio
  6. 8.1.5 Abbott Laboratories Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson HIV Diagnosis & Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson HIV Diagnosis & Treatment Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline HIV Diagnosis & Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline HIV Diagnosis & Treatment Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Gilead
  20. 8.4.1 Gilead Company Information
  21. 8.4.2 Gilead Business Overview
  22. 8.4.3 Gilead HIV Diagnosis & Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead HIV Diagnosis & Treatment Product Portfolio
  24. 8.4.5 Gilead Recent Developments
  25. 8.5 F. Hoffmann-La Roche
  26. 8.5.1 F. Hoffmann-La Roche Company Information
  27. 8.5.2 F. Hoffmann-La Roche Business Overview
  28. 8.5.3 F. Hoffmann-La Roche HIV Diagnosis & Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 F. Hoffmann-La Roche HIV Diagnosis & Treatment Product Portfolio
  30. 8.5.5 F. Hoffmann-La Roche Recent Developments
  31. 8.6 Cipla
  32. 8.6.1 Cipla Company Information
  33. 8.6.2 Cipla Business Overview
  34. 8.6.3 Cipla HIV Diagnosis & Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cipla HIV Diagnosis & Treatment Product Portfolio
  36. 8.6.5 Cipla Recent Developments
  37. 8.7 Bristol-Myers Squibb
  38. 8.7.1 Bristol-Myers Squibb Company Information
  39. 8.7.2 Bristol-Myers Squibb Business Overview
  40. 8.7.3 Bristol-Myers Squibb HIV Diagnosis & Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bristol-Myers Squibb HIV Diagnosis & Treatment Product Portfolio
  42. 8.7.5 Bristol-Myers Squibb Recent Developments
  43. 8.8 Boehringer Ingelheim
  44. 8.8.1 Boehringer Ingelheim Company Information
  45. 8.8.2 Boehringer Ingelheim Business Overview
  46. 8.8.3 Boehringer Ingelheim HIV Diagnosis & Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Boehringer Ingelheim HIV Diagnosis & Treatment Product Portfolio
  48. 8.8.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst